Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome

This prospective observational cohort study aimed to explore the clinical features of incident immune thrombocytopenia in adults and predictors of outcome, while determining if a family history of autoimmune disorder is a risk factor for immune thrombocytopenia. All adults, 18 years of age or older, recently diagnosed with immune thrombocytopenia were consecutively recruited across 21 hospital centers in France. Data were collected at diagnosis and after 12 months. Predictors of chronicity at 12 months were explored using logistic regression models. The association between family history of autoimmune disorder and the risk of developing immune thrombocytopenia was explored using a conditional logistic regression model after matching each case to 10 controls. One hundred and forty-three patients were included: 63% female, mean age 48 years old (Standard Deviation=19), and 84% presented with bleeding symptoms. Median platelet count was 10×109/L. Initial treatment was required in 82% of patients. After 12 months, only 37% of patients not subject to disease-modifying interventions achieved cure. The sole possible predictor of chronicity at 12 months was a higher platelet count at baseline [Odds Ratio 1.03; 95%CI: 1.00, 1.06]. No association was found between outcome and any of the following features: age, sex, presence of either bleeding symptoms or antinuclear antibodies at diagnosis. Likewise, family history of autoimmune disorder was not associated with incident immune thrombocytopenia. Immune thrombocytopenia in adults has been shown to progress to a chronic form in the majority of patients. A lower platelet count could be indicative of a more favorable outcome.

[1]  J. Viallard,et al.  Management of immune thrombocytopenia in adults: a population‐based analysis of the French hospital discharge database from 2009 to 2012 , 2015, British journal of haematology.

[2]  M. Lapeyre-Mestre,et al.  Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. , 2014, Blood.

[3]  M. Bruin,et al.  Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. , 2014, Blood.

[4]  G. Salles,et al.  Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. , 2014, Blood.

[5]  J. Benichou,et al.  Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects , 2014, Journal of internal medicine.

[6]  F. Roudot-thoraval,et al.  Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding , 2014, Annals of Hematology.

[7]  L. Abenhaim,et al.  A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. , 2012, Blood.

[8]  E. Andrès,et al.  Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia. , 2012, Presse medicale.

[9]  J. Logie,et al.  Prevalence of Diagnosed Adult Immune Thrombocytopenia in the United Kingdom , 2011, Advances in therapy.

[10]  H. Tamary,et al.  Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group , 2011, Haematologica.

[11]  R. Marwaha,et al.  Outcome of chronic idiopathic thrombocytopenic purpura in children , 2010, Pediatric blood & cancer.

[12]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[13]  J. Logie,et al.  The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature review , 2009, European journal of haematology.

[14]  E. L. Luning Prak,et al.  The ITP syndrome: pathogenic and clinical diversity. , 2009, Blood.

[15]  F. Mowat,et al.  Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database , 2009, British journal of haematology.

[16]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[17]  M. Michel Immune thrombocytopenic purpura: epidemiology and implications for patients , 2009, European journal of haematology. Supplementum.

[18]  M. Milhem,et al.  A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura , 2008, Annals of Hematology.

[19]  J. Segal,et al.  The epidemiology of immune thrombocytopenic purpura , 2007, Current opinion in hematology.

[20]  O. Ayyıldız,et al.  Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura , 2007, Journal of Thrombosis and Thrombolysis.

[21]  M. Paulussen,et al.  Idiopathic thrombocytopenic purpura (ITP): Is there a genetic predisposition? , 2006, Pediatric blood & cancer.

[22]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[23]  Ó. Jónsson,et al.  Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease , 2005, Acta paediatrica.

[24]  S. Vesely,et al.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. , 2004, Blood.

[25]  Ashwin P Patel Idiopathic autoimmune thrombocytopenia and neutropenia in siblings , 2002, European journal of haematology.

[26]  S. Tura,et al.  Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. , 2001, Haematologica.

[27]  P. Bierling,et al.  Screening for Autoimmune Markers Is Unnecessary during Follow-up of Adults with Autoimmune Thrombocytopenic Purpura and no Autoimmune Markers at Onset , 2000, Thrombosis and Haemostasis.

[28]  K. Schmidt,et al.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.